Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Jeff P SharmanMiklos EgyedWojciech JurczakAlan SkarbnikJohn M PagelIan W FlinnManali KamdarTalha MunirRenata WalewskaGillian CorbettLaura Maria FogliattoYair HerishanuVersha BanerjiSteven CoutreGeorge FollowsPatricia WalkerKarin KarlssonPaolo GhiaAnn JanssensFlorence CymbalistaJennifer A WoyachEmmanuelle FerrantWilliam G WierdaVeerendra MunugalavadlaTing YuMin Hui WangJohn C ByrdPublished in: Leukemia (2022)